Search Results - clinical+and+disease+specializations+%3e+neurology+%3e+neurodegeneration

39 Results

Sort By:

SCA12 Tools – SCA12 Fibroblasts, iPSCs and Polyclonal Antibodies to Investigate SCA12

Value PropositionFirst in class patient-derived biological tools for investigation of SCA12, a rare neurodegenerative disease with no known cure. Unmet NeedSpinocerebellar ataxia type 12 (SCA12) is a rare neurodegenerative disease that affects the cerebellum, commonly resulting in upper limb tremors and muscle spasms, with some patients reporting a...

Published: 1/22/2026 | Inventor(s): Russell Margolis, Pan Li, Christopher Ross

Keywords(s): Basic Research Biomarker, Cell Lines, Discovery/Research Tools, Human Cell Lines, In Vitro Research Tool

Category(s): Technology Classifications > Research Tools > Human Cell Lines, Clinical and Disease Specializations > Neurology > Neurodegeneration

Therapeutic to Block Toxic Protein Spread in Neurodegeneration

Value Proposition· Disease-Modifying Mechanism: Elevates fibrinogen-like protein 1 (FGL1) in the brain to inhibit proteinopathies (spread of toxic proteins in the brain).· Versatile Delivery Options: Flexible treatment strategies including gene therapy, exosome delivery, and blood exchange to deliver FGL1.· Dual application: Functions...

Published: 1/22/2026 | Inventor(s): Xiaobo Mao, Ted Dawson, Valina Dawson, Wenjing Wang, Junkai Hu, Mingyao Ying, Jun Wang

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology > Parkinson’s Disease, Clinical and Disease Specializations > Neurology > Parkinson's Disease, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Neurology > Alzheimer's Disease

Method to Inhibit Toxic Pathways Activated in Genetic ALS/FTD

Value PropositionTreatment readily acts via subcutaneous injection and crosses the blood-brain barrier without extra formulation or drug delivery mechanism.Treatment significantly reduces pathological and behavioral phenotypes from toxic proteins coded by genetic defects in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), which...

Published: 1/22/2026 | Inventor(s): Shuying Sun, Zhe Zhang

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Neurology > Motor Neuron Diseases, Clinical and Disease Specializations > Neurology > Dementia, Technology Classifications > Therapeutic Modalities > Peptides, Technology Classifications > Therapeutic Modalities > Targets, Technology Classifications > Diagnostics > Biomarkers

Mitigation of Nuclear Pore defect in Neurodegeneration: ESCRT Pathway Inhibition

Value PropositionNovel Target: CHMP7, a nuclear pore protein, identified as a key driver in ALS, offers a new therapeutic approach.Disease-Modifying Method: Targets the root cause of nuclear pore complex injury and neural injury, aiming to alter disease progression.Druggable Target: CHMP7 can be inhibited using small molecule, gene, and peptide therapies.Broad...

Published: 1/22/2026 | Inventor(s): Jeffrey Rothstein, Alyssa Coyne

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology > Amyotrophic Lateral Sclerosis, Clinical and Disease Specializations > Neurology > Dementia, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Huntington's Disease, Clinical and Disease Specializations > Neurology > Neurodegeneration, Technology Classifications > Therapeutic Modalities > Targets

Inhibition of rip kinases for treating neurodegenerative disorders

Unmet NeedNeurodegenerative disorders are a heterogeneous group that includes Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), dementia, and Huntington’s disease. These disorders result from progressive degeneration of the structure, function, and network of neurons in the central nervous...

Published: 1/22/2026 | Inventor(s): Seulki Lee, Han Seok Ko, Ted Dawson, Martin Pomper, Donghoon Kim, Yumin Oh, Seung-Hwan Kwon, Yong Joo Park

Keywords(s): Alzheimer's Disease, Antagonists/Inhibitors, CNS and Neurological Disorders, Disease Indication, Neurodegenerative Diseases, Parkinson's Disease, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Technology Classifications > Therapeutic Modalities > Small Molecules, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Parkinson’s Disease

Conversion of retinal glia into neurons for cell replacement therapy

Value Proposition· Identifies targets for modulation of retinal Muller glia-derived neurogenesis.· Demonstrates efficacy of adeno-associated virus induced retinal Muller glia-derived neurogenesis.· Combines viral constructs and small molecules to generate specific subtypes of retinal Muller glia-derived neurons.· Applicable...

Published: 1/22/2026 | Inventor(s): Seth Blackshaw, Thanh Hoang

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Neurology > Neurodegeneration, Technology Classifications > Therapeutic Modalities, Technology Classifications > Therapeutic Modalities > Cell Therapies

Novel Therapeutic Drug for Multiple Sclerosis

INVENTION NOVELTY This molecule, through its action on a unique target that is different from current therapeutic treatments for MS, has both immunosuppressive and neuromodulatory properties that will better prevent the progression of MS and repair the neuronal damage caused by the immune cells in MS. Currently, there are no MS drugs in the market...

Published: 1/22/2026 | Inventor(s): Paul Kim, Michael Kornberg, Peter Calabresi, Solomon Snyder

Keywords(s): Chronic Inflammatory Diseases, CNS and Neurological Disorders, Disease Indication, Multiple Sclerosis, Multiple Sclerosis (MS), Neurodegeneration, Novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

The Efficacy of Nanozyme in Neurodegenerative Diseases

Unmet NeedOxidative stress and subsequent prion-like pathology is an essential driver n the pathogenesis of neurodegenerative diseases, including Parkinson’s Disease (PD and Alzheimer’s disease (AD). Currently, only symptomatic treatments are available, and there is a great unmet need to develop a cure. Technology OverviewDisclosed herein are novel...

Published: 1/22/2026 | Inventor(s): Xiaobo Mao, Shuya Li, Weiwei He

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology > Alzheimer's Disease, Clinical and Disease Specializations > Neurology > Neurodegeneration, Clinical and Disease Specializations > Neurology > Parkinson's Disease, Clinical and Disease Specializations > Neurology > Parkinson’s Disease, Technology Classifications > Therapeutic Modalities > Proteins

Combined MAPK and NAMPT Inhibition: Greater Efficacy in Axonal Degeneration

Value PropositionDemonstrates synergistic effect of targeting two biochemical pathways.Offers possible disease-modifying therapy for degenerative diseases of the axons.Possible treatment to minimize damage from acute brain injury.Unmet NeedDegeneration of axons is a hallmark feature of various neurological conditions. Deterioration of axons is observed...

Published: 1/22/2026 | Inventor(s): Vassilis Koliatsos, Athanasios Alexandris, Jiwon Ryu

Keywords(s):

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Neurology > Neuropathy, Clinical and Disease Specializations > Neurology > Neurodegeneration

PtCu Nanozyme Scavenging ROS for Prevention of Pathologic α-Synuclein Transmission

Description: Unmet Need Parkinson’s disease (PD) is the second most common neurodegenerative disorder characterized with misfolded α-synuclein (α-syn) accumulation in Lewy bodies (LB). Although some α-syn mutations have been associated with familial PD, the majority cases are sporadic with unknown etiology. Tremendous efforts have been made to develop...

Published: 1/22/2026 | Inventor(s): Xiaobo Mao, Weiwei He, Yuqing Liu

Keywords(s):

1 2 3 4